Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  The Medicines Company    MDCO

THE MEDICINES COMPANY

(MDCO)
SummaryQuotesNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

WeissLaw LLP Investigates The Medicines Co.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/26/2019 | 05:27pm EST

NEW YORK, Nov. 26, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of The Medicines Co. ("MDCO" or the "Company") (NASDAQ: MDCO) in connection with the proposed acquisition of the Company by Swiss pharmaceutical company Novartis International A.G. Under the terms of the acquisition agreement, MDCO shareholders will receive $85.00 for each share they own.  

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own MDCO shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/the-medicines-co/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw is investigating whether MDCO's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, at least one analyst set a target price of $95.00 per MDCO share, or $10.00 above the offer price.

Additionally, prior to the acquisition announcement, MDCO announced promising results from Phase 3 of the clinical studies of Inclisiran, the Company's investigational therapy for the treatment of LDL cholesterol.  MDCO reported that the drug met "all primary and secondary efficacy endpoints, was well-tolerated and demonstrated an excellent safety profile."

Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-the-medicines-co-300965752.html

SOURCE WeissLaw LLP


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THE MEDICINES COMPANY
01/07THE MEDICINES COMPANY : Announces Effective Date of Make-Whole Fundamental Chang..
AQ
01/06THE MEDICINES COMPANY : Announces Effective Date Of Make-Whole Fundamental Chang..
BU
01/06MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
01/06MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acq..
AQ
01/06Novartis Completes Tender Offer for All Outstanding Shares in the Medicines C..
DJ
2019Monteverde & Associates PC Announces an Investigation of THE MEDICINES COMPAN..
PR
2019WeissLaw LLP Investigates The Medicines Co.
PR
2019World share markets rally on revived trade hopes; dollar gains
RE
2019World share markets rally on revived trade hopes; dollar gains
RE
2019THE MEDICINES COMPANY ALERT : Bragar Eagel & Squire, P.C. Investigates the Propo..
PR
More news